Pharmaceutical

Navigator gains $100m in Series A funding for antibody therapeutics

Navigator Medicines has secured $100m in a Series A financing round with the aim of advancing bispecific antibody therapeutics.

Aug 29, 2024 - 04:00
Navigator gains $100m in Series A funding for antibody therapeutics
Navigator Medicines has secured $100m in a Series A financing round with the aim of advancing bispecific antibody therapeutics.
Read the original article

Tags:

Previous Article

Oesophageal cancer: the global clinical trials landscape in 2024

Next Article

EC approves Astellas’ PADCEV for urothelial cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Maternal Covid-19 vaccination offers infants immunity for up to 6 months

Maternal Covid-19 vaccination offers infants immunity f...

Oct 24, 2023

STAT+: Vertex pain drug results met with measured optimism — and questions — by observers and experts

STAT+: Vertex pain drug results met with measured optim...

Jan 30, 2024

This is the TLDR of JPM Day 1

This is the TLDR of JPM Day 1

Jan 8, 2024